Analyzing electroCore (NASDAQ:ECOR) and Telomir Pharmaceuticals (NASDAQ:TELO)

Telomir Pharmaceuticals (NASDAQ:TELO) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

26.7% of electroCore shares are held by institutional investors. 13.8% of electroCore shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Telomir Pharmaceuticals and electroCore’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-566.61%	-447.89%
electroCore	-47.46%	-447.87%	-73.83%

Analyst Ratings

This is a breakdown of current recommendations for Telomir Pharmaceuticals and electroCore, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1	0	1	1	2.67
electroCore	1	0	2	0	2.33

Telomir Pharmaceuticals presently has a consensus target price of $15.00, indicating a potential upside of 994.89%. electroCore has a consensus target price of $25.50, indicating a potential upside of 275.55%. Given Telomir Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Telomir Pharmaceuticals is more favorable than electroCore.

Risk & Volatility

Telomir Pharmaceuticals has a beta of -0.49, suggesting that its stock price is 149% less volatile than the S&P 500. Comparatively, electroCore has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500.

Valuation and Earnings

This table compares Telomir Pharmaceuticals and electroCore”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$16.53 million	($0.37)	-3.70
electroCore	$29.84 million	1.82	-$11.89 million	($1.71)	-3.97

electroCore has higher revenue and earnings than Telomir Pharmaceuticals. electroCore is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

electroCore beats Telomir Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

About electroCore

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.